SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy ( n = 20) compared with healthy controls ( n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination. Treatment with anti-CD20 monoclonal antibody (aCD20) significantly reduced spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients, an effect ameliorated with longer duration from last aCD20 treatment and extent of B cell reconstitution. By contrast, all patients with MS treated with aCD20 generated antigen-specific CD4 and CD8 T cell responses after vaccination. Treatment with aCD20 skewed responses, compromising circulating follicular helper T (T FH ) cell responses and augmenting CD8 T cell induction, while preserving type 1 helper T (T H 1) cell priming. Patients with MS treated with aCD20 lacking anti-RBD IgG had the most severe defect in circulating T FH responses and more robust CD8 T cell responses. These data define the nature of the SARS-CoV-2 vaccine-induced immune landscape in aCD20-treated patients and provide insights into coordinated mRNA vaccine-induced immune responses in humans. Our findings have implications for clinical decision-making and public health policy for immunosuppressed patients including those treated with aCD20. SARS-CoV-2-specific antibodies and memory B cells are significantly reduced, but CD4 + and CD8 + T cells are robustly activated, in patients with multiple sclerosis on anti-CD20 monotherapy versus healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.
【저자키워드】 antibodies, SARS-CoV-2, multiple sclerosis, RNA vaccines, T cells, breath, 【초록키워드】 COVID-19, Treatment, public health, mRNA vaccination, vaccination, multiple sclerosis, antibody, mRNA vaccine, T cells, mRNA-1273, monoclonal antibody, memory B cells, Health policy, CD4, CD8, immune, Antigen, B cell, BNT162b2, T cell, Receptor-binding domain, mRNA, humans, immune responses, response, T cell responses, Patient, monotherapy, SARS-CoV-2-specific antibodies, patients, T cell response, memory B cell, immunosuppressed patients, anti-CD20, specific antibodies, immune protection, CD8 T cell, Immunosuppressed, Anti-RBD IgG, Messenger RNA, SARS-CoV-2-specific antibody, Most patients, healthy control, These data, healthy individuals, domain, healthy controls, priming, circulating, vaccine-induced immune response, antigen-specific antibody, CD8 T cell responses, responses, implication, Cell, memory B, robust, significantly, investigated, generate, reduced, treated, activated, ameliorated, in healthy individual, follicular, immunosuppressed patient, skewed, the SARS-CoV-2, type 1 helper, 【제목키워드】 anti-CD20 therapy, Patient, humoral immune response,